Changfeng Suyue Pharmaceutical

Changfeng Suyue Pharmaceutical (Guangzhou) Co., Ltd. is a specialized subsidiary of CF PharmTech, Inc., a leading pharmaceutical company focused on the development and commercialization of inhalation drug delivery systems. Based in Guangzhou, the company develops innovative "Class 1" and "Class 2" drugs for respiratory and pulmonary vascular diseases, including interstitial lung disease and pulmonary hypertension. Its pipeline features ICF-004, an inhaled dry powder for progressive fibrosing interstitial lung disease, and ICF-001, a long-acting inhaled prodrug for pulmonary arterial hypertension. Changfeng Suyue leverages its parent company's integrated technology platforms in particle engineering, device design, and precision delivery to address significant unmet clinical needs in the global respiratory market.